Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as on-body injector
PF-06881894 by on-body injector · 1 trial · 1 indication
Cmax of PF-06881894 was defined as maximum serum concentration of PF-06881894. Observed directly from data.
AUClast of PF-06881894 was defined as area under the serum drug concentration-time profile from time 0 to the last quantifiable concentration. Linear/Log trapezoidal method was used.
AUCinf of PF-06881894 was defined as area under the serum concentration-time profile from time 0 extrapolated to infinite time.
| Arm | Type | Description |
|---|---|---|
| PF-06881894 by on-body injector (OBI) | OTHER | PF-06881894 given by on-body injector (OBI) as test arm, 6 mg administered as a single SC injection |
| PF-06881894 by prefilled syringe (PFS) | OTHER | PF-06881894 given by prefilled syringe (PFS) as reference arm, 6 mg administered as a single SC injection |
| Name | Type | Description |
|---|---|---|
| PF-06881894 by on-body injector | COMBINATION_PRODUCT | PF-06881894 given by on-body injector (OBI), 6 mg administered as a single SC injection |
| PF-06881894 by prefilled syringe | COMBINATION_PRODUCT | PF-06881894 given by prefilled syringe (PFS), 6 mg administered as a single SC injection |
Inclusion Criteria: * Healthy male and/or female participants who, at the time of screening, are between the ages of 18 and 65 years, inclusive. * Participants will include healthy individuals, with healthy being defined as no clinically relevant abnormalities identified by a detailed medical histo...
PF-06881894 by on-body injector is an investigational small molecule therapeutic candidate developed by Pfizer, Inc. (NYSE: PFE). It is designed to be administered using an on-body injector device. The drug candidate has been studied in a Phase 1 clinical trial, but its specific therapeutic indications have not been disclosed.
PF-06881894 by on-body injector is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. Pfizer is the sponsor of the clinical program for this drug candidate.
PF-06881894 by on-body injector is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug candidate remains investigational and has not been approved by the FDA for any indication.
PF-06881894 by on-body injector has been evaluated in one completed Phase 1 clinical trial, NCT05194579. The trial was a pharmacokinetic comparability study in healthy participants, comparing the on-body injector to a prefilled syringe. It enrolled 141 participants in the United States.
PF-06881894 is administered using an on-body injector, a device designed to deliver the drug subcutaneously. A Phase 1 trial compared the pharmacokinetics of the on-body injector relative to a prefilled syringe in healthy volunteers, evaluating whether the two delivery methods are comparable.